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Under the unprecedented pressures of the global coronavirus disease
2019 (COVID‐19) pandemic, there is an urgent requisite for successful
strategies to safely deliver cardiac surgery. Severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) was first described in early
December 2019, and the rapid spread and emergence of this virus have
caused significant disruptions in the delivery of healthcare services
worldwide.1,2 In particular, the provision of cardiac surgery has been
disproportionally affected due to the reallocation of intensive care re-
sources, such as ventilators.2 Additionally, patients with pre‐existing
cardiovascular disease are likely to have comorbidities which are asso-
ciated with poorer clinical outcomes in confirmed SARS‐CoV‐2 cases.3,4
Despite this, Yandrapalli et al5 have reported the first case of a successful
coronary artery bypass graft (CABG) operation in a patient with
asymptomatic SARS‐CoV‐2 infection, which offers insights into how
cardiac surgery could be adapted to solve the challenges of this
pandemic.
In response to the burden of COVID‐19 on healthcare systems in
the UK, elective cardiac surgeries have been delayed owing to the
redistribution of intensive care resources and the unquantifiable risk
of acquiring COVID‐19.2 Likewise, cardiac surgery services have un-
dergone structural remodeling into a centralized system in an attempt
to continue provisions of emergency surgery alongside hospital man-
agement of COVID‐19 patients.2 Unsurprisingly, most cardiac surgery
units across the globe have seen a sharp decline in surgeries as a
result, and one unit reported an 83% reduction in cardiac index cases
between 23rd March to 4th May 2020.2 Similar models have been
used in Europe to manage healthcare services and increase intensive
care capacity. For example in the Lombardy region of Italy, 16 out of
20 cardiac surgical units discontinued services and all urgent cases
have been consequently diverted to the remaining four units for
centralized services.6 Although these measures have been beneficial
for supporting the focused management of COVID‐19 patients, it is
important to reflect upon the future consequences of delayed elective
cardiac surgery. Indeed, such patients are likely to have progressive
conditions and further work is needed to investigate the long‐term
impact of COVID‐19 on mortality and morbidity in this cohort.
The case report by Yandrapalli et al5 highlights the importance of
routine SARS‐CoV‐2 testing for all patients requiring cardiac surgery,
especially for detecting asymptomatic or subclinical infections. Active
SARS‐CoV‐2 infection may precipitate an overproduction of early re-
sponse proinflammatory cytokines in postoperative period, leading to
unfavorable surgical outcomes.7,8 Moreover, preliminary studies have
shown that patients with established cardiovascular diseases may have a
greater risk of increased SARS‐CoV‐2 infection severity and prognosis.9
Taken together, assessment for active infection is crucial for risk strati-
fication. In addition, clinicians should consider the threshold for surgery
when selecting patients for cardiac surgery. An international, multicenter
cohort study by COVIDSurg Collaborative which included 1128 con-
firmed SARS‐CoV‐2 patients undergoing a broad range of surgeries re-
vealed that the 30‐day mortality risk was significantly associated with the
patient demographics of male sex, an age of 70 years or older, and poor
preoperative physical health status.10 Collectively, the risks and benefits
of cardiac surgery should be carefully considered in such patients due to
higher mortality risk.10 Alternative therapeutic procedures with rapid
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discharge, such as percutaneous intervention or medical therapy, may be
more appropriate to reduce SARS‐CoV‐2 related mortality and nosoco-
mial infection risk.11
Current evidence is limited for postoperative outcomes in
cardiac surgery cases. In the aforementioned cohort study by
COVIDSurg Collaborative, the 30‐day mortality rate was 23.8%.10
In addition, the study reported that 51.2% of patients had post-
operative pulmonary complications, which was associated with a
higher mortality rate of 38.0%.10 In another case report describing
an emergency CABG operation, the asymptomatic patient suc-
cumbed to pulmonary complications arising from a SARS‐CoV‐2
infection confirmed postoperatively.12 The authors acknowledge
that the undiagnosed infection may have triggered a refractory
pathological response after cardiac surgery. Indeed, recent litera-
ture has suggested that patients with SARS‐CoV‐2 are at higher risk
of developing thromboembolisms, possibly mediated by the inter-
action with angiotensin‐converting enzyme 2 (ACE2) receptors.13
Similarly, there is a consensus that SARS‐CoV‐2 has direct adverse
effects on the myocardium due to high expression of ACE2.14 As
such, SARS‐CoV‐2 can potentially trigger multisystem complications
which require vigilant monitoring, especially in patients requiring
cardiopulmonary bypass and at high risk of developing throm-
boembolisms. Cardiac surgery patients represent a vulnerable
patient population, and this cohort may experience worse outcomes
with SARS‐CoV‐2 infection based on the currently available evi-
dence. In the latest recommendation, UK currently advises all
patients who are listed for elective cardiac surgery to self‐isolate
for 14 days before the surgery date, in a measure to limit and
contain the exposure of such cohort to the smallest possibilities of
acquiring COVID‐19.
Currently, the future of cardiac surgery after the pandemic is
unclear as the evidence is still emerging. However, the lessons
learned from these unprecedented times can be taken forward to
inform future service planning. Moving forward, routine screening of
patients for SARS‐CoV‐2 infection will undoubtedly play a key role in
identifying asymptomatic or subclinical infections. The preoperative
UK National Health Service testing recommendations should be
broadened so that all patients undergoing cardiac surgery are
screened, given the higher risk of postoperative complications in this
population. Similarly, repeat testing is important for monitoring pa-
tients for concomitant infections. Alongside changes to hospital
protocol, service delivery will inevitably shift. The successful appli-
cation of telemedicine during the pandemic has already been re-
ported in the delivery of oncology services.15 Moreover, the benefits
of telecardiology outside of the COVID‐19 era have been previously
reported, and cardiology services will likely embrace the utilization of
telemedicine for managing outpatient consultations.16 Units will also
have to address the vast backlog of surgeries caused by the cancel-
lation of elective cardiac operations in a sustainable manner,
with adequate hospital space and personal protective equipment
availability.17 To resume success services, planning for this even-
tuality should begin now and patients at significant mortality risk due
to delayed surgery need to be prioritized.
Ultimately, clear guidelines should be implemented to ensure the
safe resumption of surgical services, while also reassuring patients
concerned about safety.3 Although the future trajectory of this pan-
demic is uncertain, the insights from the impact of COVID‐19 on cardiac




1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with
2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):
497‐506. https://doi.org/10.1016/S0140-6736(20)30183-5
2. Mohamed Abdel Shafi A, Hewage S, Harky A. The impact of COVID‐19
on the provision of cardiac surgical services. J Card Surg. 2020;35(6):
1295–1297. https://doi.org/10.1111/jocs.14631
3. Khan IH, Zahra SA, Zaim S, Harky A. At the heart of COVID‐19. J Card
Surg. 2020. https://doi.org/10.1111/jocs.14596
4. Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590
patients with Covid‐19 in China: a nationwide analysis. Eur Respir J.
2020;55:2000547. https://doi.org/10.1183/13993003.00547-2020
5. Yandrapall S, Cooper H, Malekan R. Successful coronary artery bypass
operation in a SARS COV‐2 infected patient with acute coronary syn-
drome [published online ahead of print June, 2020]. J Card Surg. 2020.
6. Bonalumi G, di Mauro M, Garatti A, Barili F, Gerosa G, Parolari A. The
COVID‐19 outbreak and its impact on hospitals in Italy: the model of
cardiac surgery. Eur J Cardiothorac Surg. 2020;57:1025‐1028. https://
doi.org/10.1093/ejcts/ezaa151
7. Jose RJ, Manuel A. COVID‐19 cytokine storm: the interplay between
inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46‐e47.
https://doi.org/10.1016/S2213-2600(20)30216-2
8. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of pa-
tients undergoing surgeries during the incubation period of COVID‐19
infection. EClinicalMedicine. 2020;21:100331. https://doi.org/10.1016/j.
eclinm.2020.100331
9. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular
metabolic diseases on COVID‐19 in China. Clin Res Cardiol. 2020;
109(5):531‐538. https://doi.org/10.1007/s00392-020-01626-9
10. Archer JE, Odeh A, Ereidge S, et al. Mortality and pulmonary com-
plications in patients undergoing surgery with perioperative SARS‐
CoV‐2 infection: an international cohort study. Lancet. 2020. https://
doi.org/10.1016/S0140-6736(20)31182-X
11. Haft JW, Atluri P, Alawadi G, et al. Adult cardiac surgery during the
COVID‐19 pandemic: a tiered patient triage guidance statement. Ann
Thorac Surg. 2020. https://doi.org/10.1016/j.athoracsur.2020.04.003
12. Rescigno G, Firstenberg M, Rudez I, Uddin M, Nagarajan K,
Nikolaidis N. A case of postoperative covid‐19 infection after cardiac
surgery: Lessons learned. Heart Surg Forum. 2020;23(2):E231‐E233.
https://doi.org/10.1532/HSF.3011
13. Khan IH, Savarimuthu S, Tsun Leung MS, Harky A. The need to
manage the risk of thromboembolism in COVID‐19 patients. J Vasc
Surg. 2020;S0741‐5214.(20):31157–31165. https://doi.org/10.1016/j.
jvs.2020.05.015
14. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID‐19 and
multiorgan response. Curr Probl Cardiol. 2020;45:100618(8). https://
doi.org/10.1016/j.cpcardiol.2020.100618
15. Shirke MM, Shaikh SA, Harky A. Tele‐oncology in the COVID‐19 era:
the way forward? Trends in Cancer. 2020;S2405‐8033(20):30168–.
https://doi.org/10.1016/j.trecan.2020.05.013
16. Molinari G, Molinari M, Di Biase M, Brunetti ND. Telecardiology and its
settings of application: an update. J Telemed Telecare. 2018;24(5):373‐381.
https://doi.org/10.1177/1357633X16689432
2 | HARKY ET AL.
17. Frankel WC, Nguyen TC, Weiss AJ. Charting a safe and expeditious
course back to elective cardiac surgery during the COVID‐19 pan-
demic. Innovations. 2020:1556984520930066. https://doi.org/10.
1177/1556984520930066
How to cite this article: Harky A, Chen R, Pullan M.
Examining the impact of COVID‐19 on cardiac surgery
services: The lessons learned from this pandemic. J Card Surg.
2020;1–3. https://doi.org/10.1111/jocs.14783
HARKY ET AL. | 3
